Ask AI
ProCE Banner Activity

Advancing Pharmacist Excellence in Relapsed/Refractory Multiple Myeloma: Assessing and Managing AEs Associated With Bispecific Antibody Therapy in Multiple Myeloma

Slideset

Bispecific antibody therapy continues to rapidly change the care of patients with R/R multiple myeloma, but these drugs are associated with adverse events that must be managed for patients to remain on therapy long term. In this text module, experts provide learners with illustrated evidence-based information on CRS, ICANS, and infection. Key insights on what symptoms to monitor in patients during step-up dosing and maintenance phases are provided. Details about formulary management, REMS requirements, and standardized protocols used in multidisciplinary patient care are also discussed. 

Released: August 25, 2026

Share

Provided by

Provided by ProCE, LLC.

ProCE Banner

Supporters

Supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc

Target Audience

This activity has been designed to meet the educational needs of pharmacists and other healthcare professionals caring for patients with multiple myeloma.  

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Develop competence in multidisciplinary care coordination, including managing inpatient ramp-up and outpatient maintenance workflows, emergency department collaboration for AE emergencies, and adherence to mandated REMS requirements

  • Build skills to effectively counsel patients and caregivers on therapy expectations, AE recognition and reporting, infection prevention, adherence, and navigate equitable access challenges, especially for underserved populations